Escozul® is a groundbreaking treatment derived from the venom of the blue scorpion (Rhopalurus junceus) found in Cuba, primarily used in cancer therapy worldwide. As a leader in research and development, LifEscozul® specializes in isolating and harnessing the anti-tumoral properties of this unique venom, resulting in a patented formula known as Escozul® 202401571. The company is committed to delivering a highly individualized medical protocol, which is supported by over 500 positive clinical outcomes and collaborations with eight scientific institutions.

LifEscozul® ensures that each dose of Escozul® meets the highest safety standards, as every sample is certified in FDA-approved laboratories. The team, led by experts like Dr. Alexis Díaz, focuses on ongoing research and clinical trials to validate the therapeutic potential of blue scorpion venom. LifEscozul® also provides patients with comprehensive support, including medical consultations and updates on treatment efficacy. Through its innovative approach, the organization aims to revolutionize cancer treatment and improve patient outcomes globally.